Prior to stable cell line generation & advancement to cGMP productions, the manufacturability of a biomolecule should be assessed as a risk mitigation step. Antibody drug candidates with promising biochemical and biophysical properties can be selected at early stage of drug development. At LakePharma, a series of fast and small-scale tests, as well as in silico predictive tools are employed to serve as an additional selection criteria for better and safer therapeutic leads.
View LakePharma PDF file on Antibody Developability Analysis.
Please contact LakePharma at email@example.com for custom quotes and details.